Morpholino oligonucleotides useful in cancer treatment
US10857174B2 · kind B2 · utility
0Cited by
10References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 25, 2019 |
| Grant date | Dec 8, 2020 |
| Priority date | — |
| Expiry date | Jul 25, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4162
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.